ProCE Banner Activity

Hepatitis B Reactivation and Low-level Viremia in People Living With HIV

Conference Coverage
Clinical Thought

Studies from IDWeek 2023 shed light on the risk of virologic failure in low-level viremia and the risk of hepatitis B reactivation after switching to an ART without HBV activity.

Released: November 09, 2023

Share

Faculty

Daniel R Kuritzkes

Daniel R Kuritzkes, MD

Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc., Janssen Therapeutics, Division of Janssen Products, LP, Merck & Co., Inc., Rahway, NJ, USA and ViiV Healthcare.

Gilead Sciences, Inc.

Janssen Therapeutics, Division of Janssen Products, LP

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Disclosure

Primary Author

Daniel R Kuritzkes, MD

Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel R. Kuritzkes, MD: consultant/advisor/speaker: AbbVie, Gilead, GlaxoSmithKline, Immgenuity, Janssen, Merck, Roche, ViiV; researcher: Gilead, Merck, ViiV.